Compound that prevents replication of SARS-CoV-2 identified by researchers
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
List view / Grid view
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
Researchers have discovered new drug compounds that target the SKI complex of SARS-CoV-2, preventing replication.
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
The SARS-CoV-2 RNA genome structure has been studied by researchers who identified several potential drug targets.
After viral pneumonia in elderly mice, there is an accumulation of dysfunctional tissue-resident memory T cells in the lungs which scientists suggest may drive chronic inflammation and fibrosis.
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.
A team has revealed how SARS-CoV-2 infects cells, suggesting that targeting its RNA with drugs would stop the virus replicating.
Anti-inflammatory therapies for inflammatory bowel disease could aid recovery from COVID-19 as they target an enzyme involved in both diseases.
Researchers have found that aprotinin, an approved drug for influenza in Russia, combats SARS-CoV-2 in cells.
Researchers have found the genome of COVID-19 and infected cell syncytia in the respiratory cells of deceased patients, potentially explaining long-term coronavirus effects.
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.